Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

INOVIQ - Notice of Annual General Meeting (ASX:IIQ)

Melbourne, Australia, 27 October 2022: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) advises that INOVIQ’s 2022 Annual General Meeting (AGM) is to be held at the offices of Grant Thornton, ...read more

INOVIQ - Receipt of R&D Tax Incentive Refund (ASX:IIQ)

INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) is pleased to advise that the Company has received $865,625 from the federal government’s Research and Development (R&D) Tax Ince...read more

INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform (ASX:IIQ)

Highlights: Contract Research Agreement signed with Nicoya to transfer, develop and evaluate a SubB2M-based Surface Plasmon Resonance (SPR) test on the Alto™ Digital ...read more

INOVIQ - 2022 Annual Report and update on results (ASX:IIQ)

INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) is pleased to release its Annual Report for the 2022 financial year. The Company reported a total comprehensive loss for the year of $6.260m in th...read more

INOVIQ - Appendix 4E and Preliminary Financial Report (ASX:IIQ)

To view the Appendix and Preliminary Financial Report, download the attached PDF.

INOVIQ Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

INOVIQ - Appendix 4C & Quarterly Activities Report - June 2022 (ASX:IIQ)

INOVIQ Limited (ASX:IIQ) today released its Appendix 4C and Quarterly Business Update for the quarter ended 30 June 2022. For more information, download the attached PDF.

INOVIQ - Positive SubB2M IHC Results for Melanoma (ASX:IIQ)

-- Immunohistochemistry (IHC) feasibility study successfully completed using INOVIQ’s SubB2M probe to aid in diagnosis of malignant melanoma in tis...read more

INOVIQ - hTERT US Patent Granted (ASX:IIQ)

Highlights -- US Patent No 11,391,738 granted covering the hTERT technology -- Provides further IP protection for hTERT in the USA for cancer applications beyond bladder cancer Melbourne,&nbs...read more

INOVIQ Engages Sales Team to Accelerate EXO-NET Roll-out (ASX:IIQ)

-- INOVIQ engages US-based Percorso Life Sciences to provide contract sales force and logistics services to accelerate commercial roll-out of EXO-NET® products in the USA -- Contract sales forc...read more

INOVIQ - SubB2M US Patent Grant and Program Update (ASX:IIQ)

Melbourne, Australia, 1 July 2022: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) announces that United States of America Patent No 11,371,033 entitled ‘Subtilase cytotoxin B subunit mutant&...read more

INOVIQ Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

INOVIQ - Australian Patent Granted for SubB2M Technology (ASX:IIQ)

* AU Patent No 2017358401 granted covering the SubB2M technology * Provides IP protection in Australia for SubB2M-based diagnostics INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) announc...read more

INOVIQ Key Manufacturing Agreement to Advance SubB2M tests (ASX:IIQ)

* INOVIQ has executed a Master Manufacturing Agreement with MP Biomedicals for production of the SubB2M protein for the Company’s SubB2M-based tests * INOVIQ’s SubB2M technology detects...read more

INOVIQ Appendix 4C & Quarterly Activities Report - March 2022 (ASX:IIQ)

* Collaboration with the University of Queensland (UQ) expanded to develop a worldfirst exosome-based ovarian cancer screening test * ResearchDx, a US-based specialty contract diagnostics organisat...read more

Viewing: 46 - 60 of 111 Previous | Next